Health Care Spending Flattens as U.S. Results Stagger

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A new study from research firm IMS shows that new and better treatments for disease and a dip in physician visits steadied health care spending in the United States last year. It should be considered good news for a country in which the costs of health care have run wild for years. “The Use of Medicines in the United States: Review of 2011” reports, among other things, that “physician office visits and non-emergency room hospital admissions dropped.” The trend may not matter much, except financially. The U.S. continues to be the nation that spends the most per capita for medical treatment only to get mediocre results.

IMS reports that “Total healthcare system spending on medicines reached $320 billion in 2011, up 0.5 percent on a real per capita basis, or 3.7 percent in nominal terms.” The extremely small rise was attributed in part to a rough economy. That means a recovery could cause costs to rise again.

The Commonwealth Fund issued research in 2011 that showed that, in 2008, Americans spent at least twice as much as all other developed nations on a per capita basis. And Americans got poor results compared to most of the nations. Studies by the Organisation for Economic Co-operation and Development and the Council on Foreign Relations found about the same. The OECD study reported that, among its 34 members, Americans spent $8,000 a year in 2010 on health care, the most of any nation by far. Life expectancy, however, was the eighth worse.

The IMS study explains that new medications and a trend toward fewer physician visits could be a key to health care spending, which may eventually stabilize on a per capita basis in the U.S. The research does not discuss that these costs are still extremely high compared to the rest of the developed world. Most data demonstrate that U.S. health care spending has little relationship to patient health, so a cessation in its increase is only good economic news. The trend almost certainly will not alter results.

Douglas A. McIntyre

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618